1
|
Kopetskyi V, Antoniv M, Yarema R, Maksymovskyi V, Chetverikova-Ovchinnik V, Kryzhevskyi V, Volodko N, Gushchin V, Nikiforchin A. Building an Efficient Peritoneal Surface Malignancies Program Despite the Lower-Middle-Income Barriers: Ukraine Experience. JCO Glob Oncol 2024; 10:e2300432. [PMID: 38330272 DOI: 10.1200/go.23.00432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 11/26/2023] [Accepted: 12/04/2023] [Indexed: 02/10/2024] Open
Abstract
PURPOSE Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) programs are often limited to centers in developed countries because of extensive requirements. We aimed to analyze efficacy and challenges of CRS/HIPEC centers in lower-middle-income settings in the Ukraine example. METHODS A multicenter descriptive study was conducted using data sets (2008-2022) from Kyiv, Lviv, and Odesa centers. Patients with appendiceal neoplasm (AN); colorectal cancer (CRC); malignant peritoneal mesothelioma (MPM); and epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC) treated with CRS ± HIPEC were included. Overall survival (OS) was analyzed for N ≥ 20 cohorts using the Kaplan-Meier method. RESULTS We included 596 patients. At Kyiv and Lviv centers, 37 and 28 patients with AN had completeness of cytoreduction (CC-0/1) rates of 84% and 71%, respectively. Thirty-day major morbidity stood at 24% and 18%, respectively. Median OS was not reached (NR) at both centers. Nineteen patients with CRC from Kyiv, 11 from Lviv, and 156 from Odesa had CC-0/1 rates of 84%, 91%, and 86%, respectively. Thirty-day major complications occurred in 16%, 18%, and 8%, respectively. Median OS in the Odesa cohort was 35 (95% CI, 32 to 38) months. Among 15 Kyiv, five Lviv, and six Odesa patients with MPM, CC-0/1 rates were 67%, 80%, and 100%, respectively, while major complications occurred in 13%, 0%, and 17%, respectively. OS was not analyzed because of small MPM cohorts. At Kyiv, Lviv, and Odesa centers, 91, 40, and 89 patients, respectively, had primary EOC. CC-0/1 rates were 79%, 100%, and 80%, and 30-day major morbidity rates were 23%, 5%, and 6%, respectively. Median OS was NR, 71 (95% CI, 32 to 110), and 67 (95% CI, 61 to 73) months, respectively. CONCLUSION CRS/HIPEC programs in lower-middle-income environment can achieve safety and survival that meet global standards. Our discussion highlights common obstacles in such settings and proposes effective overcoming strategies.
Collapse
Affiliation(s)
- Viacheslav Kopetskyi
- Department of Hepatopancreatobiliary Surgery, National Cancer Institute, Kyiv, Ukraine
| | - Marta Antoniv
- Department of Surgery, Ordensklinikum Linz, Linz, Austria
| | - Roman Yarema
- Department of Oncology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
| | | | | | - Vitalii Kryzhevskyi
- Department of Hepatopancreatobiliary Surgery, National Cancer Institute, Kyiv, Ukraine
| | - Nataliya Volodko
- Department of Oncology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
| | - Vadim Gushchin
- Department of Surgical Oncology, Mercy Medical Center, Baltimore, MD
| | | |
Collapse
|
2
|
Cos H, Shen P. Comparison of outcomes between surgical treatment of colorectal cancer metastatic to the liver and the peritoneum: Review of the literature. J Surg Oncol 2024; 129:85-90. [PMID: 37990864 DOI: 10.1002/jso.27524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 11/07/2023] [Indexed: 11/23/2023]
Abstract
BACKGROUND Liver and peritoneum are two of the most common sites of colorectal metastases. METHODS We searched for articles comparing outcomes of surgical management for metastatic colorectal cancer to the liver and peritoneum. CONCLUSION Cytoreductive surgery/heated intraperitoneal chemotherapy has a similar safety profile and survival outcomes as hepatectomy for colorectal metastases after stratifying by resection status and should be incorporated earlier in the management algorithm for colorectal cancer patients with peritoneal metastases METHODS: We performed a wide search on PubMed, EMBASE, and Google Scholar for articles comparing outcomes of surgical management for metastatic colorectal cancer to the liver and peritoneum. We focused on studies comparing their perioperative clinical outcomes as well as their oncological outcomes. The following words were included in the search: comparison, outcomes, metastasectomy, colorectal cancer, liver, peritoneal surface disease, hepatectomy, and cytoreduction. RESULTS One hundred and twenty studies were evaluated. Six of these studies met the criteria for this review.
Collapse
Affiliation(s)
- Heidy Cos
- Atrium Health Wake Forest Baptist Medical Center, Section Surgical Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Perry Shen
- Atrium Health Wake Forest Baptist Medical Center, Section Surgical Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| |
Collapse
|
3
|
Wong JSM, Ng IAT, Paik B, Ong CAJ, Seo CJ, Lee PP, Zhu HY, Chia CS. Attitudes, knowledge & awareness amongst physicians in the management of peritoneal-surface based malignancies. Asian J Surg 2022; 45:2829-2831. [PMID: 35753924 DOI: 10.1016/j.asjsur.2022.06.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 06/10/2022] [Indexed: 12/15/2022] Open
Affiliation(s)
- Jolene Si Min Wong
- Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Outram Road, Singapore General Hospital, Singapore, 169608, Singapore; SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore; SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore
| | - Irene Ai Ting Ng
- Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Outram Road, Singapore General Hospital, Singapore, 169608, Singapore
| | - Benjamin Paik
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - Chin-Ann Johnny Ong
- Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Outram Road, Singapore General Hospital, Singapore, 169608, Singapore; SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore; SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore; Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore; Institute of Molecular and Cell Biology, A∗STAR Research Entities, 1 Fusionopolis Way, Singapore, 13863, Singapore
| | - Chin Jin Seo
- Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Outram Road, Singapore General Hospital, Singapore, 169608, Singapore; SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore; SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore
| | - Piea Peng Lee
- Division of Surgery and Surgical Oncology, National Cancer Center, Singapore
| | - Hong-Yuan Zhu
- Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Outram Road, Singapore General Hospital, Singapore, 169608, Singapore; Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore
| | - Claramae Shulyn Chia
- Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Outram Road, Singapore General Hospital, Singapore, 169608, Singapore; SingHealth Duke-NUS Oncology Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore; SingHealth Duke-NUS Surgery Academic Clinical Program, Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore.
| |
Collapse
|
4
|
Souadka A, Essangri H, Makni A, Abid M, Ayadi M, Ksantini F, Kordjani Z, Ballah Y, Bouka J, Benkabbou A, Majbar MA, El Khannoussi B, Mohsine R, Boutayeb S, Hubner M. Current Opinion and Practice on Peritoneal Carcinomatosis Management: The North African Perspective. Front Surg 2022; 9:798523. [PMID: 35350143 PMCID: PMC8957835 DOI: 10.3389/fsurg.2022.798523] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 01/20/2022] [Indexed: 11/30/2022] Open
Abstract
Background The status of peritoneal surface malignancy (PSM) management in North Africa is undetermined. The aim of this study was to assess and compare current practice and knowledge regarding PSM and examine satisfaction with available treatment options and need for alternative therapies in North Africa. Methods This is a qualitative study involving specialists participating in PSM management in North Africa. The survey analyzed demographic characteristics and current knowledge and opinions regarding PSM management in different institutions. We also looked at goals and priorities, satisfaction with treatment modalities and heated intraperitoneal chemotherapy (HIPEC) usefulness according to specialty, country, years of experience, and activity sector. Results One-hundred and three participants responded to the survey (response rate of 57%), including oncologists and surgeons. 59.2% of respondents had more than 10 years experience and 45.6% treated 20–50 PSM cases annually. Participants satisfaction with PSM treatment modalities was mild for gastric cancer (3/10 [IQR 2–3]) and moderate for colorectal (5/10 [IQR 3–5]), ovarian (5/10 [IQR 3–5]), and pseudomyxoma peritonei (5/10 [IQR 3–5]) type of malignancies. Good quality of life and symptom relief were rated as main priorities for treatment and the need for new treatment modalities was rated 9/10 [IQR 8–9]. The perceived usefulness of systemic chemotherapy in first intention was described as high by 42.7 and 39.8% of respondents for PSM of colorectal and gastric origins, while HIPEC was described as highly useful for ovarian (49.5%) and PMP (73.8) malignancies. Conclusions The management of PSM in the North African region has distinct differences in knowledge, treatments availability and priorities. Disparities are also noted according to specialty, country, years of expertise, and activity sector. The creation of referral structures and PSM networks could be a step forward to standardized PSM management in the region.
Collapse
Affiliation(s)
- Amine Souadka
- Surgical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco
- *Correspondence: Amine Souadka
| | - Hajar Essangri
- Surgical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco
| | - Amin Makni
- Surgical Department A, Rabta Hospital, Tunis, Tunisia
| | - Mourad Abid
- Surgical Oncology Department, Batna Cancer Institute, Batna, Algeria
| | - Mouna Ayadi
- Medical Oncology Department, Salah-Azaiz Institute, Tunis, Tunisia
| | - Feriel Ksantini
- Medical Oncology Department, Salah-Azaiz Institute, Tunis, Tunisia
| | - Zakia Kordjani
- Surgical Oncology Department, Batna Cancer Institute, Batna, Algeria
| | - Yousri Ballah
- Surgical Oncology Department, Batna Cancer Institute, Batna, Algeria
| | - Jemila Bouka
- Surgical Oncology Department, National Institute of Oncology, Nouakchott, Mauritania
| | - Amine Benkabbou
- Surgical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco
| | - Mohammed Anass Majbar
- Surgical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco
| | - Basma El Khannoussi
- Pathology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco
| | - Raouf Mohsine
- Surgical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco
| | - Saber Boutayeb
- Medical Oncology Department, National Institute of Oncology, University Mohammed V, Rabat, Morocco
| | - Martin Hubner
- Department of Visceral Surgery, University Hospital Centre Hospitalier Universitaire Vaudois and University of Lausanne (UNIL), Lausanne, Switzerland
| |
Collapse
|
5
|
Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, Huy NT, Marušić A, Paul CL, Kwok J, Karbwang J, de Waure C, Drummond FJ, Kizawa Y, Taal E, Vermeulen J, Lee GHM, Gyedu A, To KG, Verra ML, Jacqz-Aigrain ÉM, Leclercq WKG, Salminen ST, Sherbourne CD, Mintzes B, Lozano S, Tran US, Matsui M, Karamouzian M. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med 2021; 36:3179-3187. [PMID: 33886027 PMCID: PMC8481359 DOI: 10.1007/s11606-021-06737-1] [Citation(s) in RCA: 607] [Impact Index Per Article: 202.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 03/17/2021] [Indexed: 02/05/2023]
Affiliation(s)
- Akash Sharma
- University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, Delhi, India.,Online Research Club, Nagasaki, Japan
| | - Nguyen Tran Minh Duc
- Online Research Club, Nagasaki, Japan.,Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
| | - Tai Luu Lam Thang
- Online Research Club, Nagasaki, Japan.,Department of Emergency, City's Children Hospital, Ho Chi Minh City, Vietnam
| | - Nguyen Hai Nam
- Online Research Club, Nagasaki, Japan.,Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Sze Jia Ng
- Online Research Club, Nagasaki, Japan.,Department of Medicine, Crozer Chester Medical Center, Upland, PA, USA
| | - Kirellos Said Abbas
- Online Research Club, Nagasaki, Japan.,Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Nguyen Tien Huy
- Institute of Tropical Medicine (NEKKEN) and School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, 852-8523, Japan.
| | - Ana Marušić
- Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia
| | - Christine L Paul
- School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
| | - Janette Kwok
- Division of Transplantation and Immunogenetics, Department of Pathology, Queen Mary Hospital Hong Kong, Pok Fu Lam, Hong Kong
| | - Juntra Karbwang
- School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, 852-8523, Japan
| | - Chiara de Waure
- Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | | | - Yoshiyuki Kizawa
- Department of Palliative Medicine, Kobe University School of Medicine, Hyogo, Japan
| | - Erik Taal
- Department of Psychology, Health & Technology, Faculty of Behavioural, Management and Social Sciences, University of Twente, Enschede, Netherlands
| | - Joeri Vermeulen
- Department of Public Health, Biostatistics and Medical Informatics Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.,Department of Health Care, Knowledge Centre Brussels Integrated Care, Erasmus Brussels University of Applied Sciences and Arts, Brussels, Belgium
| | - Gillian H M Lee
- Paediatric Dentistry and Orthodontics, Faculty of Dentistry, University of Hong Kong, Pok Fu Lam, Hong Kong
| | - Adam Gyedu
- Department of Surgery, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Kien Gia To
- Faculty of Public Health, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
| | - Martin L Verra
- Department of Physiotherapy, Bern University Hospital, Insel Group, Bern, Switzerland
| | | | - Wouter K G Leclercq
- Department of Surgery, Máxima Medical Center, Veldhoven, Veldhoven, the Netherlands
| | - Simo T Salminen
- Department of Social Psychology, University of Helsinki, Helsinki, Finland
| | | | - Barbara Mintzes
- School of Pharmacy and Charles Perkins Centrey, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Sergi Lozano
- School of Economics, University of Barcelona, Barcelona, Spain
| | - Ulrich S Tran
- Department of Cognition, Emotion, and Methods in Psychology, School of Psychology, University of Vienna, Vienna, Austria
| | - Mitsuaki Matsui
- School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, 852-8523, Japan
| | - Mohammad Karamouzian
- School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.,HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
| |
Collapse
|
6
|
Francescutti VA, Skitzki JJ, Kane JM, Simunovic M. Barriers to Referral for CS/HIPEC Identified Using a Tailoring Grid Methodology: Interviews With Stakeholders in New York State. J Surg Res 2021; 267:235-242. [PMID: 34157492 DOI: 10.1016/j.jss.2021.04.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Revised: 01/22/2021] [Accepted: 04/26/2021] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Cytoreduction and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has variable uptake, with referrals reliant on other physicians. To characterize barriers to referral for CS/HIPEC, we created a pragmatic "tailoring grid", incorporating the concepts of Pathman's 4 As of awareness, agreement, adoption, and adherence and barriers acting at the individual, practice group, and organization level. METHODS AND MATERIALS We invited surgeons and medical oncologists from Western New York State who potentially refer patients for CS/HIPEC to participate in tailoring grid interviews. RESULTS Interviews of 10 surgeons and 10 medical oncologists were completed. The participants were positioned in the Pathman 4 A's with respect to referrals for CS/HIPEC as follows: (1) A 19 aware (1 not aware); (2) A 3 in agreement (17 not in agreement); (3) A 9 adopters; and (4) A 6 adherent. Among the 9 participants who had referred at least one patient for CS/HIPEC (adopters/adherent), only 2 were in agreement with the appropriateness of CS/HIPEC. Barriers to awareness of included lack of interaction with colleagues and knowledge of indications. Barriers to agreement included lack of high quality of evidence supporting CS/HIPEC such as well-designed RCTs. Barriers to adoption included lack of communication with CS/HIPEC surgeons; lack of inclusion of the procedure into algorithms and defined morbidity/mortality rates. Barriers to adherence included lack of inclusion into guidelines by major societies; perceptions that the procedure is resource-intensive; lack of defined quality measures. CONCLUSIONS The tailoring grid efficiently identified barriers to awareness, agreement, adoption and adherence for routine referral for CS/HIPEC. Barriers to increased referrals included lack of high-quality evidence supporting CS/HIPEC. Barriers more easily addressed included communication between referring and CS/HIPEC surgeons, and outcomes at the individual patient and hospital level.
Collapse
Affiliation(s)
- Valerie A Francescutti
- Division of General Surgery, Department of Surgery, McMaster University and Juravinski Cancer Center, Hamilton, Ontario, Canada..
| | - Joseph J Skitzki
- Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
| | - John M Kane
- Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
| | - Marko Simunovic
- Division of General Surgery, Department of Surgery, McMaster University and Juravinski Cancer Center, Hamilton, Ontario, Canada
| |
Collapse
|
7
|
Bin Traiki TA, AlShammari SA, AlOtaibi WS, AlAnazi SN, Alnmry MM, Albdah AM, Alhassan NS. The attitude and practice of general surgeons toward cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A cross-sectional study. Ann Med Surg (Lond) 2021; 66:102440. [PMID: 34141418 PMCID: PMC8187938 DOI: 10.1016/j.amsu.2021.102440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 05/20/2021] [Accepted: 05/23/2021] [Indexed: 11/19/2022] Open
Abstract
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) mandate well-established HIPEC and oncology centers, which are not available in many medical institutions. This study assessed the knowledge, attitude, and practice toward CRS and HIPEC of general surgeons in Riyadh, Saudi Arabia. Patients and methods General surgeons (n = 266) from nine hospitals who treat patients with gastrointestinal cancer were surveyed. The responses of surgeons who work in HIPEC and academic centers (Group A) and surgeons working in tertiary and secondary hospitals (Group B) were compared. The survey response rate was 48.1% (128/266). Results Surgeons in group B treated significantly more patients with peritoneal carcinomatosis per year than surgeons in group A (P = .001). Group B reported having a HIPEC specialist at their hospital, and 71.4% reported that the nearest HIPEC center was within 30 miles, compared to 4.5% of respondents in group A (P = .001). Lack of access to a HIPEC specialist was reported by 15.5% of surgeons in group B and 0% of surgeons in group A (P = .006). HIPEC as a possible therapeutic option for appendiceal cancer was cited by 60.7% of surgeons in group B compared to 84.1% of surgeons in group A (P = .007) and as a therapeutic option for ovarian cancer by 52.4% of surgeons in group B and 81.8% of surgeons in group A (P = .001). Conclusion New strategies are needed to improve the knowledge and implementation of the referral system for HIPEC among general surgeons. Our study was limited by a low response rate. Exposure to HIPEC centers during residency or fellowship training was reported by half of our respondents. Surgeons in tertiary and secondary hospitals treated significantly more patients with peritoneal carcinomatosis per year than surgeons in HIPEC and academic centers. Lack of access to a HIPEC specialist was significantly reported by surgeons working in tertiary and secondary hospitals. HIPEC was significantly cited as an option for appendiceal cancer by surgeons in HIPEC and academic centers compared to surgeons in tertiary and secondary hospitals.
Collapse
Affiliation(s)
- Thamer A Bin Traiki
- Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, 11461, Saudi Arabia
| | - Sulaiman A AlShammari
- Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, 11461, Saudi Arabia
| | - Wadha S AlOtaibi
- Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, 11461, Saudi Arabia
| | - Shahad N AlAnazi
- Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, 11461, Saudi Arabia
| | - Mashal M Alnmry
- Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, 11461, Saudi Arabia
| | - Abdullah M Albdah
- Trauma and Acute Care Surgery Fellow, Department of Surgery, King Saud University Medical City, King Saud University, Riyadh, 11461, Saudi Arabia
| | - Noura S Alhassan
- Colorectal Research Chair, Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, 11461, Saudi Arabia
| |
Collapse
|
8
|
Liu K, Zhu J, Song YX, Wang X, Zhou KC, Lu Y, Liu XQ. Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis. Front Oncol 2020; 10:29. [PMID: 32117709 PMCID: PMC7015071 DOI: 10.3389/fonc.2020.00029] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Accepted: 01/09/2020] [Indexed: 12/24/2022] Open
Abstract
Background: Non-muscle invasive bladder cancer accounts for nearly 80% of newly diagnosed bladder cancer cases, which often recur and progress. This meta-analysis was evaluated by the adverse events and recurrence rate of thermal intravesical chemotherapy vs. normal temperature intravesical chemotherapy in the treatment of non-muscle invasive bladder cancer. Methods: A systematic review and cumulative analysis of studies reporting adverse events and recurrence rate of thermal intravesical chemotherapy vs. normal temperature intravesical chemotherapy was performed through a comprehensive search of Pubmed, Embase, Cochranelibrary.com, CNKI, Wanfang Med Online database and VIP database. All analyses were performed using the Revman manager 5. Result: Twelve studies (11 randomized controlled trials and 1 retrospective study) including 888 patients, 445 in the thermal intravesical chemotherapy group, and 443 in the normal temperature intravesical chemotherapy group, met the eligibility criteria. Patients in the thermal intravesical chemotherapy group had a lower risk of disease recurrence than those who had normal temperature intravesical chemotherapy (24 months follow-up group: RR = 0.30, 95% CI: 0.21-0.43, P < 0.00001, I 2 = 0%; 36 months follow-up group: RR = 0.27, 95% CI: 0.14-0.54, P = 0.0002, I 2 = 0%) while no significant difference in adverse events rate (RR = 0.89, 95% CI = 0.53-1.52; P = 0.67, I 2 = 78%). Conclusions: When compared with normal temperature intravesical chemotherapy, thermal intravesical chemotherapy can reduce the recurrence rate without increasing incidence of adverse events in patients with non-muscle invasive bladder cancer.
Collapse
Affiliation(s)
- Kang Liu
- Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
| | - Jun Zhu
- Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
| | - Yu-Xuan Song
- Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
| | - Xiao Wang
- Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
| | - Ke-Chong Zhou
- Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
| | - Yi Lu
- Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
| | - Xiao-Qiang Liu
- Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
| |
Collapse
|